Mahmoud Reza Jaafari Selected Research

Ligands

1/2023	AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study.
12/2022	Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
10/2022	A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells.
2/2022	Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides.
12/2021	pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
9/2019	Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment.
4/2018	Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
1/2018	The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.
6/2017	PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.
4/2016	Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mahmoud Reza Jaafari Research Topics

Disease

115	Neoplasms (Cancer) 04/2024 - 06/2010
33	Breast Neoplasms (Breast Cancer) 09/2022 - 01/2014
23	Carcinoma (Carcinomatosis) 04/2024 - 12/2013
20	Melanoma (Melanoma, Malignant) 10/2023 - 12/2015
16	Leishmaniasis 10/2021 - 06/2012
11	Cutaneous Leishmaniasis 10/2021 - 07/2012
10	Colonic Neoplasms (Colon Cancer) 04/2024 - 10/2013
8	Infections 10/2021 - 07/2012
7	Atherosclerosis 05/2023 - 07/2016
6	COVID-19 01/2023 - 10/2020
6	Inflammation (Inflammations) 01/2023 - 01/2019
5	Cardiotoxicity 04/2023 - 10/2013
5	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2016
4	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 01/2019
3	Hypoxia (Hypoxemia) 01/2022 - 09/2019
3	Dyslipidemias (Dyslipidemia) 01/2021 - 05/2015
3	Hypersensitivity (Allergy) 10/2020 - 07/2015
2	Virus Diseases (Viral Diseases) 01/2024 - 10/2022
2	Multiple Sclerosis 12/2023 - 12/2021
2	Liver Failure 10/2023 - 10/2020
2	Hyperthermia 03/2023 - 01/2017
2	Pain (Aches) 01/2022 - 01/2022
2	Autoimmune Diseases (Autoimmune Disease) 12/2021 - 11/2021
2	Body Weight (Weight, Body) 11/2021 - 03/2019
2	Stroke (Strokes) 10/2021 - 02/2018
2	Diabetes Mellitus 01/2021 - 09/2016
2	Neoplasm Metastasis (Metastasis) 09/2020 - 09/2020
2	Wounds and Injuries (Trauma) 07/2020 - 03/2019

Drug/Important Bio-Agent (IBA)

61	Liposomes (Liposome)IBA 04/2024 - 11/2009
50	VaccinesIBA 01/2024 - 07/2012
43	Peptides (Polypeptides)IBA 10/2023 - 07/2012
25	AntigensIBA 10/2023 - 07/2012
24	liposomal doxorubicin (Doxil)FDA Link 04/2024 - 12/2013
19	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2023 - 12/2013
14	CurcuminIBA 01/2023 - 01/2018
12	Therapeutic UsesIBA 05/2023 - 04/2015
12	LigandsIBA 01/2023 - 12/2013
10	Proteins (Proteins, Gene)FDA Link 01/2023 - 07/2012
9	EnzymesIBA 10/2022 - 11/2014
8	MicroRNAs (MicroRNA)IBA 02/2018 - 01/2016
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2016
7	1-dodecylpyridoxal (PLD)IBA 12/2022 - 12/2013
6	Protein Subunit VaccinesIBA 07/2023 - 01/2015
6	1,2- dioleoyloxy- 3- (trimethylammonium)propaneIBA 10/2022 - 12/2013
6	Monoclonal AntibodiesIBA 10/2021 - 11/2015
6	CPG-oligonucleotideIBA 01/2021 - 11/2014
6	EpitopesIBA 01/2020 - 07/2012
5	Phospholipids (Phosphatides)FDA LinkGeneric 04/2024 - 10/2014
5	Cancer VaccinesIBA 10/2023 - 01/2019
5	Small Interfering RNA (siRNA)IBA 10/2022 - 04/2015
5	Amphotericin B (Amphotericin)FDA LinkGeneric 10/2021 - 12/2015
5	AntibodiesIBA 01/2021 - 11/2015
4	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 11/2012
4	Cisplatin (Platino)FDA LinkGeneric 07/2022 - 10/2014
4	CholesterolIBA 04/2020 - 11/2014
4	OligodeoxyribonucleotidesIBA 07/2018 - 06/2012
3	ChitosanIBA 11/2023 - 12/2018
3	Messenger RNA (mRNA)IBA 10/2023 - 01/2022
3	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 08/2023 - 01/2015
3	Docetaxel (Taxotere)FDA Link 09/2022 - 09/2016
3	AntioxidantsIBA 03/2022 - 01/2018
3	LipidsIBA 02/2022 - 08/2019
3	CytokinesIBA 10/2021 - 11/2014
3	galbanic acidIBA 07/2021 - 01/2019
3	arginyl-glycyl-aspartic acidIBA 07/2021 - 12/2013
3	Nucleotide AptamersIBA 01/2021 - 06/2015
3	Glutathione (Reduced Glutathione)IBA 11/2020 - 03/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 06/2019 - 06/2010
3	human ERBB2 proteinIBA 02/2019 - 06/2015
3	Epirubicin (Ellence)FDA LinkGeneric 01/2016 - 10/2013
2	Imiquimod (Aldara)FDA LinkGeneric 12/2023 - 01/2018
2	Lipid NanoparticlesIBA 12/2023 - 01/2023
2	APTIBA 11/2023 - 10/2013
2	Antineoplastic Agents (Antineoplastics)IBA 11/2023 - 10/2017
2	Silicon Dioxide (Silica)FDA LinkGeneric 11/2023 - 01/2015
2	Silybin (Lagosa)IBA 10/2023 - 12/2021
2	Amino Acids FDA Link 07/2022 - 04/2016
2	DiarylheptanoidsIBA 03/2022 - 08/2021
2	ErbB Receptors (EGF Receptor)IBA 02/2022 - 01/2018
2	fosbretabulin (combretastatin A4)IBA 02/2022 - 09/2019
2	bis(p-chlorophenyl)acetic acid (DDA)IBA 01/2022 - 12/2019
2	Malondialdehyde (Propanedial)IBA 10/2021 - 03/2019
2	MicellesIBA 10/2021 - 10/2020
2	Meglumine AntimoniateIBA 10/2021 - 05/2019
2	coumarinIBA 07/2021 - 01/2019
2	SesquiterpenesIBA 07/2021 - 01/2019
2	Hormones (Hormone)IBA 04/2021 - 04/2018
2	LeptinIBA 04/2021 - 04/2018
2	peptide AIBA 01/2021 - 01/2014
2	Epithelial Cell Adhesion MoleculeIBA 01/2021 - 05/2020
2	Streptozocin (Streptozotocin)FDA Link 01/2021 - 07/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2020 - 12/2019

Therapy/Procedure

46	Therapeutics 12/2023 - 10/2012
21	Immunotherapy 01/2023 - 01/2015
7	Drug Therapy (Chemotherapy) 10/2022 - 10/2013
3	Injections 01/2024 - 07/2020
3	Subcutaneous Injections 01/2022 - 11/2014
2	Radiotherapy 03/2023 - 03/2019
2	Intravenous Administration 01/2023 - 09/2016
2	Aftercare (After-Treatment) 01/2022 - 09/2015